Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK043 in Advanced Solid Tumors
NCT04964375Phase 1Unknown
- Sponsor
- Abbisko Therapeutics
- Start
- Aug 2021
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lumipodlin in solid tumor, melanoma, microsatellite instability-high cancer and 1 more, sponsored by Abbisko Therapeutics. Primary endpoints: Dose Limiting Toxicity and Incidence and Severity of Adverse Events at 6 months. Status: unknown.
02
Drugs
lumipodlin
03
Conditions
solid tumormelanomamicrosatellite instability-high cancermismatch repair deficient solid tumor
Beyond the preview
Go deeper on NCT04964375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04964375.